These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 5022451)

  • 21. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH
    J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
    [No Abstract]   [Full Text] [Related]  

  • 22. [Study of 3-4-dihydroxyphenylacetic acid, a dopamine catabolite, in patients with Parkinson's disease before treatment with L-dopa].
    Samson M; Bohuon C; Augustin P; Comoy E; Pouliquen A
    Rev Neurol (Paris); 1972 Aug; 127(2):315-7. PubMed ID: 4666641
    [No Abstract]   [Full Text] [Related]  

  • 23. [The therapeutic use of L-DOPA in Parkinson's disease. Biochemical, pharmacological and clinical considerations].
    Morselli PL; Rizzo M; Tognoni G
    Recenti Prog Med; 1970 Feb; 48(2):97-124. PubMed ID: 5467589
    [No Abstract]   [Full Text] [Related]  

  • 24. Iso-homovanillic acid determination in cerebrospinal fluid and in urine during L-DOPA treatment of Parkinson's disease.
    Ebinger G; Adriaenssens K
    Clin Chim Acta; 1973 Nov; 48(4):427-31. PubMed ID: 4761590
    [No Abstract]   [Full Text] [Related]  

  • 25. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.
    Muenter MD; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1972 Jun; 47(6):389-95. PubMed ID: 5041685
    [No Abstract]   [Full Text] [Related]  

  • 26. Biochemical investigations in patients with Parkinson's disease treated with L-dopa.
    Jequier E; Dufresne JJ
    Neurology; 1972 Jan; 22(1):15-21. PubMed ID: 5061836
    [No Abstract]   [Full Text] [Related]  

  • 27. Metabolism of levodopa in patients with Parkinson's disease. Radioactive and fluorometric assays.
    Morgan JP; Bianchine JR; Spiegel HE; Rivera-Calimlim L; Hersey RM
    Arch Neurol; 1971 Jul; 25(1):39-44. PubMed ID: 5146410
    [No Abstract]   [Full Text] [Related]  

  • 28. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

  • 29. [L-dopa effect in Parkinson's syndrome].
    Römer F; Bettag W; Bock WJ
    Z Allgemeinmed; 1971 Feb; 47(6):281-3. PubMed ID: 5571715
    [No Abstract]   [Full Text] [Related]  

  • 30. [Treatment of Parkinson's disease with L-dopa].
    Guglielmi L; Vecchi L
    Clin Ter; 1970 May; 53(3):259-69. PubMed ID: 4917328
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effects of L-dopa or amantadine treatment on the spindles of sleep in Parkinson's syndromes].
    Puca FM; Bricolo A; Turella G
    Rev Neurol (Paris); 1972 Aug; 127(2):313. PubMed ID: 4666639
    [No Abstract]   [Full Text] [Related]  

  • 32. Metabolism of dopa in Parkinsonism.
    Sandler M; Karoum F; Ruthven CR
    N Engl J Med; 1969 Dec; 281(25):1429. PubMed ID: 5355467
    [No Abstract]   [Full Text] [Related]  

  • 33. L-dopa for Parkinson's disease; some limitations in its use.
    Gillen HW
    Med Trial Tech Q; 1973; 19(4):400-8. PubMed ID: 4710961
    [No Abstract]   [Full Text] [Related]  

  • 34. [Dopa and decarboxylase inhibitors in Parkinson's disease].
    Pakkenberg H
    Ugeskr Laeger; 1974 Feb; 136(7):377. PubMed ID: 4821980
    [No Abstract]   [Full Text] [Related]  

  • 35. Influence of L-dopa on the EEG and EMG in Parkinson patients.
    Visser SL; Postma JU
    Psychiatr Neurol Neurochir; 1971; 74(4):315-21. PubMed ID: 5146237
    [No Abstract]   [Full Text] [Related]  

  • 36. Therapeutic implications in Parkinsonism of m-tyramine formation from L-dopa in man.
    Sandler M; Goodwin BL; Ruthven CR
    Nature; 1971 Feb; 229(5284):414-5. PubMed ID: 4926994
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of L-dopa treatment on the speech of patients with Parkinson's disease.
    Audelman JU; Hoel RL; Lassman FM
    Neurology; 1970 Apr; 20(4):410-1. PubMed ID: 5535064
    [No Abstract]   [Full Text] [Related]  

  • 38. L-dopa therapy in parkinsonism: mechanism of action.
    Sandler M
    Psychiatr Neurol Neurochir; 1971; 74(4):331-3. PubMed ID: 5146239
    [No Abstract]   [Full Text] [Related]  

  • 39. L-DOPA treatment in Parkinson's disease: effect on dopamine and related substances in discrete brain regions.
    Davidson L; Lloyd K; Dankova J; Hornykiewicz O
    Experientia; 1971 Sep; 27(9):1048-9. PubMed ID: 5116129
    [No Abstract]   [Full Text] [Related]  

  • 40. L-dopa therapy in Parkinson's disease.
    Murray TJ
    N S Med Bull; 1972 Jun; 51(3):67-70. PubMed ID: 4504954
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.